Dr Jeremie Calais talks about the emergence and importance of PSMA-targeted radioligand therapy. Alicia Morgans, MD: Nuclear medicine specialists play a big role in particular as we talk about ...
Extended prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (177 Lu-PSMA) beyond six cycles is an effective and well-tolerated treatment for metastatic castration-resistant ...
Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all other treatment options, a new study now demonstrates that the therapy is ...
The researchers also assessed a prognostic biomarker, fluorodeoxyglucose (FDG) PET. A high volume of disease on FDG-PET (metabolic tumor volume [MTV] > 200 mL) was associated with a worse prognosis ...
Longitudinal PRO modeling, rather than time-to-worsening censoring, indicated maintained HRQOL and pain outcomes with radioligand intensification despite early on-treatment score fluctuations. FACT-P ...
A new machine-learning approach for prostate-specific membrane antigen (PSMA) treatment of metastatic castration-resistant prostate cancer (mCRPC) could estimate radiation dose to tumors and healthy ...
According to the publication's first author, Bastiaan Privé, PSMA therapy may play a significant role in treating limited metastatic prostate cancer. ' We see that we can postpone more burdensome ...
Reston, VA—Extended prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (177 Lu-PSMA) beyond six cycles is an effective and well-tolerated treatment for metastatic ...
Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all other treatment options, a new study now demonstrates that the therapy is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results